• OncoDiag has fully developped and validated Urodiag, a simple urine test for the surveillance of bladder cancer (NMIBC). It will be on the market in 2021.

    Two other tests are in the validation process and should be available in 2022:

    – Prostadiag, a test to determine the agressivity level of prostate cancer to help urologists to choose the best treatment and to reduce the number of surgery,

    – Colodiag, a simple blood test to screen population for early detection of colorectal cancer.